spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

Partnerships in Clinical Trials Europe 2017

28-29 November 2017
RAI, Amsterdam

PCT Europe is back, bringing you the latest information from across the clinical trials spectrum and providing you with direct access to the industry's leading innovators. And this year, we're in Amsterdam!

Topics for 2017 include:
• Partnerships and Collaboration
• Investigator and industry: How can they work together?
• Mobile eHealth
• Governance, Oversight and Quality
• Partnership Management
• Patients as Partners
• Disruptive Innovation, Technology and Big Data
• Small to Mid-Size Pharma and Biotech

PLUS, this year benefit from a full 2 days of content dedicated to Clinical Trial Supply and Early Clinical Development in our co-located meetings.

Visit the website to find out more: lifesciences.knect365.com/pct-europe

Book now to secure your place alongside 1000+ clinical professionals this November, ask your questions, and put yourself at the centre of the discussion.

 
Print this page
Send to a friend
   
spacer
Industry Events

Vaccine Manufacturing

23-25 April 2018, RAI, Amsterdam

Changing the shape of vaccine development, manufacturing and delivery.
More info >>

Banner of Clinical_Trial_New_England_events_95 on Samedan

Banner of BIO_Europe_Events_102 on Samedan
White Papers

Clinical Trials in Ukraine: Orange Paper Overview and 1st Half Year 2014

Synergy Research Group

The Orange Paper is an analytical report about the clinical trials market in Russia, published quarterly by the contract research organization Synergy Research Group. The first edition of Orange Paper was released in 2006, and at the moment 31 issues have already published. Now, thanks to Synergy Group Ukraine, obtaining information about the market of clinical trials in Ukraine has become possible. In Ukraine, during the period from 1996 to 2013, applicants had obtained 3,864 positive conclusions about the possibility of conducting clinical trials of drugs, both for domestic and foreign manufacturers, including conduct of multinational multi-center clinical trials (hereinafter – MMCTs)
More info >>


News and Press Releases

Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure

WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new agreement which grants Charles River commercial access to AstraZeneca’s (NYSE: AZN) high-throughput screening (HTS) and compound management infrastructure. Through the agreement, Charles River will perform HTS programs for its clients utilizing AstraZeneca’s state-of-the-art HTS facility.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement